ArticleObesity surgery2026
Roux-en-Y Gastric Bypass Produces Sustained Uric Acid Reduction and Near-Elimination of Hyperuricemia at 24 Months - A Single-Center Longitudinal Cohort Study.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObesity is a major and well-established risk factor for hyperuricemia and gout. Metabolic and bariatric surgery (MBS) is associated with marked and sustained improvements in metabolic health. The long-term trajectory of serum uric acid (UA) levels after Roux-en-Y gastric bypass (RYGB) is incompletely characterized. In this study, we sought to describe the evolution of serum UA concentrations during the first 24 months after RYGB.
methodsWe performed a single-center longitudinal cohort study of adults undergoing RYGB between 2015 and 2023. Serum UA was measured preoperatively (baseline) and at 6, 12, and 24 months postoperatively. Temporal trends in UA were examined using linear mixed effects models. The prevalence of hyperuricemia (UA >7.0 mg/dL in men, UA >6.0 mg/dL in women) was compared across time points using paired McNemar tests. Multivariable regression analyses were conducted to identify independent predictors of UA levels at 24 months.
resultsNinety-four patients were analyzed (mean baseline BMI, 54.1 kg/m2; 31.9% male). Mean serum UA levels decreased from 7.34 mg/dL at baseline to 6.13, 5.13, and 4.71 mg/dL at 6, 12, and 24 months, respectively, which corresponds to a mean reduction of 2.64 mg/dL from baseline to 24 months (p < 0.001). Male sex was consistently associated with higher UA levels at all time points (mean difference, +0.97 mg/dL; p < 0.001) without evidence of a sex-by-time interaction (p = 0.97). The prevalence of hyperuricemia decreased from 57.4% preoperatively to 33.0%, 9.8%, and 2.2% at 6, 12, and 24 months, respectively. At 24 months postoperatively, 96% of subjects with baseline hyperuricemia had achieved normouricemia. In multivariable analyses, higher baseline serum UA (β = 0.176 per mg/dL; p < 0.001) and male sex (β = 0.848; p < 0.001) independently predicted 24-month serum UA concentrations.
conclusionsRYGB was associated with substantial and sustained reductions in serum UA and marked resolution of hyperuricemia during 24 months of follow-up. Higher baseline UA concentrations and male sex were independently associated with higher UA levels at 24 months. Larger prospective studies are warranted to confirm these findings and evaluate their clinical implications.
Indexed as
Identifiers
42742828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.